Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
There has been substantial evolution in the treatment of metastatic renal cell carcinoma with notable changes in the first-line setting. Currently, doublet combination therapy with either two immune checkpoint inhibitors or a combination of an immune checkpoint and tyrosine kinase inhibitor is consi...
Saved in:
Main Authors: | Georges Gebrael (Author), Kamal Kant Sahu (Author), Neeraj Agarwal (Author), Benjamin L. Maughan (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
by: SiNi Li, et al.
Published: (2021) -
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
by: Yuexin Xu, et al.
Published: (2021) -
Gut microbiota and immunotherapy of renal cell carcinoma
by: Stefano Bibbò, et al.
Published: (2023) -
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
by: Ernesto Rossi, et al.
Published: (2023) -
Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment
by: Clio Dessinioti, et al.
Published: (2023)